IL-6 protein: A key messenger of inflammation, closely associated with various major diseases

Interleukin-6 (IL-6) is a pleiotropic cytokine and a key signaling molecule in the human immune system. This protein is produced by various cells, including immune cells (such as T cells, B cells, macrophages), endothelial cells, fibroblasts, and certain tumor cells. By binding to its receptor (IL-6R) and activating the JAK/STAT signaling pathway, IL-6 exerts a wide range of biological effects in the body.

 

The normal functions of IL-6 include:

 

Immune regulation: Promotes the differentiation of B cells into plasma cells, which produce antibodies

 

Inflammatory response: Coordinates immune responses at sites of infection or injury

 

Hematopoiesis: Stimulates the differentiation of hematopoietic stem cells

 

Acute-phase response: Induces the liver to produce acute-phase proteins such as C-reactive protein (CRP)

 

Metabolic regulation: Participates in energy metabolism and body temperature regulation

 

IL-6 and Disease Associations: A Dual Role from Protection to Harm

 

1. Autoimmune Diseases

 

Rheumatoid Arthritis (RA)

 

IL-6 plays a central role in the pathogenesis of RA. It promotes the infiltration of inflammatory cells into the synovium, stimulates osteoclast differentiation leading to bone erosion, and contributes to systemic symptoms such as fatigue and anemia. Anti-IL-6 receptor drugs (e.g., tocilizumab) have become an important treatment option for RA.

 

Systemic Lupus Erythematosus (SLE)

 

Elevated IL-6 levels promote the activation of autoreactive B cells and the production of autoantibodies, exacerbating disease activity.

 

2. Cytokine Storm and Severe Infections

 

In severe infections (such as sepsis and severe COVID-19), IL-6 is a key mediator of the "cytokine storm." This uncontrolled inflammatory response can lead to multiple organ failure, and IL-6 levels are directly correlated with disease severity and mortality. IL-6 inhibitors have shown therapeutic effects in severe COVID-19 patients.

 

3. Castleman Disease

 

This rare lymphoproliferative disorder is directly linked to excessive IL-6 production, and anti-IL-6 therapy (e.g., siltuximab) has become its standard treatment.

 

4. Juvenile Idiopathic Arthritis (JIA)

 

Patients with systemic JIA exhibit significantly elevated IL-6 levels, which are closely associated with fever, joint symptoms, and growth retardation.

 

5. Cardiovascular Diseases

 

Chronic inflammation is a key driver of atherosclerosis. IL-6 promotes vascular inflammation, plaque instability, and thrombosis. Studies show that IL-6 levels are an independent predictor of myocardial infarction risk.

 

6. Cancer

 

IL-6 has a dual role in the tumor microenvironment:

 

Pro-tumor effects:

 

Promotes tumor cell proliferation, survival, invasion, and metastasis

 

Regulation of tumor immunity:

 

Inhibits anti-tumor immune responses and promotes immune evasion

 

Elevated IL-6 levels are associated with poor prognosis in various cancers (e.g., multiple myeloma, ovarian cancer, prostate cancer, lung cancer).

 

7. Metabolic Diseases

 

Type 2 Diabetes

 

IL-6 plays a role in the development of insulin resistance, serving both as an inflammatory marker and directly interfering with insulin signaling.

 

Obesity

 

Adipose tissue is a significant source of IL-6, and the chronic low-grade inflammatory state links obesity to metabolic syndrome.

 

8. Neurological Diseases

 

Depression

 

The "inflammatory depression" subtype is associated with elevated IL-6 levels, and IL-6 may contribute to depressive pathology by affecting neurotransmitter metabolism and neuroplasticity.

 

Alzheimer's Disease

 

IL-6 participates in neuroinflammatory processes, potentially exacerbating β-amyloid deposition and tau protein hyperphosphorylation.

 

9. Fibrotic Diseases

 

IL-6 promotes fibroblast activation and extracellular matrix deposition, playing a role in diseases such as pulmonary fibrosis and liver fibrosis.

 

IL-6 Targeted Therapy: A Breakthrough in Precision Intervention

 

Given the central role of IL-6 in various diseases, targeted drugs against the IL-6 signaling pathway have been successfully applied in clinical practice:

 

Tocilizumab: An anti-IL-6 receptor monoclonal antibody approved for RA, JIA, giant cell arteritis, and severe COVID-19

 

Siltuximab: Directly neutralizes IL-6 and is used for Castleman disease

 

Sarilumab: An anti-IL-6 receptor monoclonal antibody used for RA treatment

 

Various investigational drugs: New drugs targeting different aspects of the IL-6 signaling pathway are under development

 

Detection and Monitoring: IL-6 as a Biomarker

 

Serum IL-6 testing has clinical value in the following areas:

 

Assessing the activity of inflammatory diseases

 

Predicting the severity and prognosis of infections

 

Monitoring the progression and treatment response of certain cancers

 

Guiding personalized selection of targeted therapies

 

Future Prospects

 

The field of IL-6 research continues to advance rapidly, with future directions including:

 

Developing more precise IL-6 pathway inhibitors

 

Exploring the specific mechanisms of IL-6 in different diseases

 

Studying the temporal dynamics and spatial distribution of IL-6 signaling

 

Developing personalized treatment strategies based on IL-6

 

Summary

 

As a core regulator of the immune system, the IL-6 protein maintains immune balance under physiological conditions but becomes a common pathway in various diseases under pathological conditions. From autoimmune diseases to cancer, metabolic disorders to neuropsychiatric diseases, abnormal expression and signaling of IL-6 are involved in a wide range of human disease processes. A deeper understanding of its mechanisms not only reveals the intrinsic connections between diseases but also provides new insights for developing targeted therapies across diseases. With the advancement of precision medicine, intervention strategies targeting the IL-6 pathway will demonstrate therapeutic potential in more disease areas, offering new hope to patients.